Tango reported early clinical results showing its PRMT5 inhibitor vopimetostat may add to daraxonrasib activity in metastatic pancreatic ductal adenocarcinoma, lifting the response profile in a Phase I/II setting. According to the data described, the combination produced durable responses in patients with MTAP-deleted and RAS-mutant disease, with investors focused on both objective response rate and progression-free survival signals at interim follow-up. The reporting also fed expectations for subsequent development planning, with attention on whether the combo can replicate or extend response durability seen in other investigational combinations targeting oncogenic signaling. Key takeaway: the early add-on readout strengthens the case for PRMT5-node modulation as a partnership-friendly strategy in PDAC combination regimens.